dorzagliatin + metformin

Dorzagliatin + metformin is a **combination therapy** studied for the treatment of **type 2 diabetes mellitus (T2D)** in patients with inadequate glycemic control on metformin alone. Dorzagliatin (HMS5552) is a novel, orally bioavailable, dual-acting **glucokinase activator** (GKA) targeting both pancreatic and hepatic glucokinase, enhancing glucose-stimulated insulin secretion and reducing hepatic glucose production in a glucose-dependent manner. Metformin is a first-line oral antihyperglycemic agent that reduces hepatic glucose output and improves insulin sensitivity. Clinical trials have demonstrated that the **combination improves glycemic control (reducing HbA1c and postprandial glucose)** beyond metformin alone, with an additive effect and a good safety profile, including absence of severe hypoglycemia or significant drug-drug interactions[1][3][4].

Other names

dorzagliatin + metforminHMS5552 + metformin